NVG-291 in Spinal Cord Injury Subjects
Conditions
Spinal Cord Injuries · Chronic Spinal Cord Injury · Subacute Spinal Cord Injury
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Shirley Ryan AbilityLab, Chicago, Illinois, United States
Study leads
Randall Kaye, M.D.
Study Director
NervGen Pharma
No study contact email or phone is listed for this trial.